Supplementary Material for: Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment

Hepatocellular carcinoma is one of the leading causes of cancer-related death not only in Japan, but also worldwide. In the advanced stage, hepatic arterial infusion chemotherapy (HAIC) is one of the most commonly used treatment options for liver cancer in Japan and implantation of a catheter system (called a port system) in the body is a treatment method that has evolved mainly in Japan. The Guideline Committee of the Japanese Society of Interventional Radiology and the Japanese Society of Implantable Port Assisted Treatment jointly developed clinical practice guidelines for HAIC with a port system to ensure its appropriate and safe performance and these were published in Japanese in 2018. We have now written an updated English version of the guidelines with the aim of making this treatment widely known to experts around the world. In this article, the evidence, method, indication, treatment regimen, and maintenance of the system are summarized.

肝细胞癌（Hepatocellular carcinoma）不仅是日本，亦是全球范围内癌症相关死亡的主要诱因之一。于晚期阶段，肝动脉灌注化疗（hepatic arterial infusion chemotherapy, HAIC）是日本临床应用最为广泛的肝癌治疗手段之一；而体内植入导管系统（亦称港入式给药系统，port system）则是日本本土发展成熟的特色治疗方式。日本介入放射学会（Japanese Society of Interventional Radiology）指南委员会与日本植入式给药辅助治疗学会（Japanese Society of Implantable Port Assisted Treatment）联合制定了针对HAIC联合港入式给药系统的临床实践指南，以保障该疗法的规范、安全开展，并于2018年以日文版正式发布。本次我们完成了该指南英文版本的更新译制，旨在将这一治疗方案推广至全球范围内的专业领域人士。本文对该疗法的循证依据、操作方法、适应证、治疗方案以及系统维护要点进行了系统性总结。